Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ALTAREX CORP. (TSE: AXO) -- Ignore unavailable to you. Want to Upgrade?

To: Mark J. Redmond who wrote (268)	12/22/2000 9:15:26 PM
From: DaveAu	Read Replies (1) \| Respond to of 274

Mark, I think a lot of people have been turned off of this one. They definitely have a poor fiscal track record - continually diluting existing shareholders with new issues at low prices. On the other hand, Richard Bagley does have a track record of bringing products to market with larger companies. The company is also very open with investors. I think one issue holding the stock back may also be that the scientific community hasn't yet accepted their work. The enhanced immune response due to HAMA goes against prevailing theories. BIOM on the other hand is loved by everyone and the market cap shows it. I expect BIOM to do well and its definitely a safer choice but AXO at 1.20 could easily be a 10 bagger in 12 months. I know it sounds like I'm pumping but I'm not a trader. I don't plan to sell anytime soon. Dave P.S. DMX, FMI, ISA, SYB also look like good value if you're looking at Canadian bio techs.